|Description||Durvalumab (Imfinzi) is a human IgG1κ monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of cancer. It was developed by Medimmune/AstraZeneca. Durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody which blocks the interaction of PD-L1 with the PD-1 and CD80 molecules.
GenScript Anti-Durvalumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Durvalumab.
|Purification||Antigen affinity column|
|Concentration||0.5 mg/ml, lyophilized with PBS, pH 7.4, containing 0.02% sodium azide.|
|Reconstitution||Reconstitute the lyophilized antibody with deionized water (or equivalent) to a final concentration of 0.5 mg/ml.|
|Specificity||The product is specific for Durvalumab.|
|Storage||The lyophilized product remains stable up to 1 year at -20 °C from date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8 °C or for up to 12 months at -20 °C or below. Avoid repeated freezing and thawing cycles.|
|Note||GenScript can customize this product per customer's request including product size, buffer components, etc.|
|Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.
ELISA detection: 0.01-0.1 µg/ml
Other applications: user-optimized
ELISA binding of Anti-Durvalumab Antibody (GenScript, A02010-40) with Durvalumab. While the antibody does not recognize the human IgG Fc fragment (data not shown).
Coating antigen: Durvalumab, 1 µg/ml.
Anti-Durvalumab Antibody (GenScript, A02010-40) dilutions start from 1,000 ng/ml.
EC₅₀= 7.301 ng/ml.
For more documents, please visit "Technical Support".